Archive

Posts tagged under: clinical trials

Curious about what to expect at ASCO 2017? ta-Scan has you covered!

As ASCO 2017 kicks off this Friday, finding the information relevant to you can be a hassle. Using ta-Scan, you can quickly uncover key information about sponsors, clinical trials, drugs and investigators contributing to ASCO this year. To help you out, we highlight a few interesting points.

asco 2017 abstracts

Abstracts

Over the past 3 years, there have been some notable changes in therapeutic areas discussed at the American Society of Clinical Oncology’s annual meeting. It comes as no surprise that the Immune Oncology trend is growing year on year, much like Lung Cancer. On the other hand, interest in Breast Cancer is steadily declining, which could be due to the disappointing results of Immune Oncology within Breast Cancer. Another interesting fact is the gain in Gastrointestinal Cancer abstracts at this year’s conference, after a relatively quiet 2016.

asco 2017 abstracts ta distribution

Sponsor & trial activity

Of the 1,203 clinical trials that are cited at ASCO 2017, 6 key commercial sponsors have seen considerable fluctuations in trial activity when compared to ASCO 2016. Significant gains can be seen in the trial activity of BMS, Pfizer, and Roche, whereas Novartis, Sanofi, and Johnson & Johnson have seen a decrease in trial numbers.

asco 2017 abstracts ta distribution

ta-Scan’s top 5 drugs to watch at ASCO 2017

With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

asco 2017 abstracts pd-pd-l

Investigator & sponsor collaborations

Looking at the percentage of top Oncology experts used by the leading commercial sponsors of trials talked about at ASCO 2017, it’s clear that Roche and Merck have an evenly distributed usage of investigators in both the USA as well as Europe, whereas others seem to lean toward USA investigator preference.

asco 2017 abstracts top oncology investigators

ta-Scan’s top 5 drugs to watch at ASCO 2017

With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

asco 2017 abstracts new drugs

Learn more about ta-Scan

Interested in ta-Scan‘s analytical services? Request your free webinar here or contact us.

Presenting at the Patient Recruitment and Retention Summit in London, 21-23 February 2017

Our next meeting will happen in London this month: MDCPartners will present at the 9th Annual Patient Recruitment and Retention Summit 2017, which will take place in the London Marriott Hotel Kensington during 21-23 February 2017. Hot topics during this meeting:

  • What role does clinical research have on patients?
  • How to make trials more valuable for patients?
  • New regulations and the impact on clinical trials
  • Developing a robust clinical trial recruitment and retention strategy
  • What makes a good feasibility process?
  • How to keep the site staff motivated and engaged?

Click here to request the full event agenda.

Utilizing Big Data to Enhance Patient Recruitment

On Wednesday 22 February 2017 at 11:45 AM MDCPartners’ Strategic Analyst in Oncology, Dr Jonathan Crowther, will talk about:

Utilizing big data to enhance patient recruitment: Analyzing public information for trial feasibility and site selection

The path to clinical trial success is burdened with underperforming site selection, poor patient recruitment and frequent delays. Such barriers result in failures to meet targets and dwindling statistical significance. Comprehensive planning via a feasibility survey can alleviate these issues however, it has been suggested that the accuracy of a survey may be below 10%. As big data becomes more applicable in the clinical trial setting, capitalizing on the wealth of publicly available clinical data is essential. The clinical business intelligence platform ta-Scan semantically links trial, investigator and site information to provide a robust feasibility analysis to help address the following questions:

  • Estimation of appropriate patient cohorts
  • Key Opinion Leaders in the field
  • Competing and historic trials across the therapeutic area
  • Suitable geographic setting for a trial
  • IRB and timing issues that may affect trial start-up

Join us in London

Would you like to join us in London this month to learn more about how to leverage big data for patient recruitment or to see how our real-world data evidence solutions can help with clinical trial planning challenges? Let us know to arrange a meeting with our Technical Product Manager Kristof Geentjens and our Strategic Analyst in Oncology Dr Jonathan Crowther. Or just pop by at booth #5!

ta-Scan Infomercial

Learn more about the concepts of our ta-Scan software in this video highlighting pharmaceutical industry data deficiencies and ta-Scan’s solutions.

Categories

 

Tags

 

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page